A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).

Annick Desjardins,David A. Reardon,J. J. Vredenburgh,Katherine B. Peters,Mohit Trikha,Joyce James,M. Gardner,Alise Brickhouse,James E. Herndon,Henry S. Friedman

A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).

2011

Annick Desjardins
David A. Reardon
J. J. Vredenburgh
Katherine B. Peters
Mohit Trikha
Joyce James
M. Gardner
Alise Brickhouse
James E. Herndon
Henry S. Friedman

2070 Background: AC480 is a novel oral tyrosine kinase inhibitor of the human epidermal growth factor receptor family, especially EGFR and HER2. EGFR is an important therapeutic target in MG. We pe...

Keywords:

Drug
Glioma
Anesthesia
Pharmacokinetics
Medicine
Enzyme
Pharmacology
Tyrosine-kinase inhibitor
antiepileptic drug
in patient
Human Epidermal Growth Factor Receptor Family

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations